Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bleeding Complications
100%
Mortality Complications
100%
Acute Stroke
100%
Stroke Mortality
100%
Alteplase
100%
Tenecteplase
100%
Intracranial Hemorrhage
55%
Mortality Rate
33%
Blood Transfusion
33%
Risk Ratio
33%
Patients with Stroke
22%
Low Mortality
22%
Subgroup Analysis
22%
Blood Loss
22%
Thrombolytic Agents
22%
Healthcare Organizations
22%
TriNetX
22%
Academic Medical Centers
11%
Initial Treatment
11%
Low Risk
11%
Safety Profile
11%
Clinical Diagnostics
11%
Ischemic Stroke
11%
Acute Ischemic Stroke
11%
Demographic Information
11%
Low Dose Rate
11%
Cost-effectiveness
11%
Between-group
11%
Randomized Controlled Trial
11%
Thrombolysis
11%
Diagnosis-related Groups
11%
Mortality Profiles
11%
Intravenous Thrombolysis
11%
Major Bleeding
11%
Trial Data
11%
Propensity Score Matching
11%
Temporal Difference
11%
Safety Outcomes
11%
Efficacy Outcomes
11%
Retrospective multicenter Study
11%
Operational Advantages
11%
Acute Ischemic Stroke Treatment
11%
10-year Data
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bleeding
100%
Alteplase
100%
Cerebrovascular Accident
100%
Tenecteplase
100%
Brain Hemorrhage
55%
Mortality Rate
33%
Brain Ischemia
33%
Fibrinolytic Agent
22%
Retrospective Study
11%
Randomized Controlled Trial
11%
Neuroscience
Alteplase
100%
Tenecteplase
100%
Cerebrovascular Accident
100%
Cerebral Hemorrhage
55%
Brain Ischemia
33%
Thrombolytic Drug
22%
Randomized Controlled Trial
11%